Apollo Laboratory Science and Technology Services

Apollo Laboratory Science and Technology Services was paid $2.82M by Medicaid between Jul 2018 and Apr 2023, across 30 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 48% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#16 of 73

Median peer was paid$95K

This provider vs. median30×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	8,205	$268K
2019	28,819	$1.16M
2020	12,279	$382K
2021	18,678	$586K
2022	13,573	$389K
2023	1,008	$43K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	48%	28,985	17,379	$1.36M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	33%	30,818	18,591	$943K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	5.8%	5,776	3,896	$163K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.0%	1,040	818	$85K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.9%	1,780	976	$82K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.2%	256	247	$62K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.8%	4,789	3,262	$50K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.6%	5,770	3,890	$46K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	255	247	$9K
82652		<1%	268	263	$5K
87581		<1%	255	247	$4K
87486		<1%	255	247	$4K

18 more codes

84443	Thyroid stimulating hormone (TSH)	<1%	335	$2K
80053	Comprehensive metabolic panel	<1%	371	$2K
82607		<1%	237	$2K
80061	Lipid panel	<1%	299	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	365	$1K
82746		<1%	135	$937.69
83036	Hemoglobin; glycosylated (A1C)	<1%	194	$789.46
84439		<1%	127	$494.81
83735		<1%	59	$165.97
84480		<1%	16	$153.16
84436		<1%	46	$131.34
82728		<1%	23	$100.32
86703		<1%	12	$94.28
86803		<1%	12	$91.20
83540		<1%	33	$89.58
87086	Culture, bacterial; quantitative colony count, urine	<1%	17	$71.06
82570		0%	17	$0.00
84311		0%	17	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSHEETS, KIM (CREDENTIALING ADMINISTRATIVE)

Same official

Other billing entities under SHEETS, KIM

Full network →

Provider	Location	Paid
Compliance Advantage LLC	Nicholasville, KY	$156K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.